GlaxoSmithKline Pharmaceuticals (GSK) has reported its financial results for the third quarter ended September 2009. The company has reported 12% increase in net sales as compared to the previous quarter, while profit before investment income and taxes grew by 13% on a comparable basis.
Hasit Joshipura, managing director at GSK, said: “Sales during the quarter have shown growth across mass, mass speciality, vaccines and speciality therapies. Recent launches of Tykerb for refractory breast cancer, Benitec an anti-hypertensive drug from Daiichi Sankyo and Cervarix for cervical cancer are making steady progress. Vaccines have recorded strong growth with the rotaviral diarrhea vaccine tracking ahead of plan”.
GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc. The GSK India product portfolio includes prescription medicines and vaccines. Their prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, cardiovascular disease and respiratory diseases. GSK also offers a range of vaccines for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus and others.